Treatment of Severe Immune Thrombocytopenic Purpura Associated with COVID-19

Nayab Ahmed; Abdullah Asreb; Rosemary Chofor; Achenef Melese

doi:10.12659/AJCR.932557

21 October 2021 : Case report USA

Treatment of Severe Immune Thrombocytopenic Purpura Associated with COVID-19

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology

Nayab Ahmed^1AEF*, Abdullah Asreb^1EF, Rosemary Chofor^1EF, Achenef Melese^1AEF

DOI: 10.12659/AJCR.932557

Am J Case Rep 2021; 22:e932557

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 2. The figure depicts the change in the platelet count over a period of 4 weeks over which the patient continued to receive prednisone and weekly rituximab. Week 0 depicts the platelet count on the day of discharge, post first dose of rituximab. Over the course of 4 weeks, the platelet count continued to trend upward.

Back to the Article

Treatment of Severe Immune Thrombocytopenic Purpura Associated with COVID-19

Your Privacy